Steven Cohen Ultragenyx Pharmaceutical Inc. Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 976,052 shares of RARE stock, worth $26.9 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
976,052
Previous 976,052
-0.0%
Holding current value
$26.9 Million
Previous $35.3 Million
-0.0%
% of portfolio
0.09%
Previous 0.09%
Shares
29 transactions
Others Institutions Holding RARE
# of Institutions
338Shares Held
89.4MCall Options Held
1.08MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA10MShares$275 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$154 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$115 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$88.6 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$72.1 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $1.93B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...